Change in the treatment strategy for pediatric Crohn's disease
Crohn's disease is characterized by chronic inflammation involving any portion of the gastrointestinal tract. Treating Crohn's disease is a major challenge for clinicians, as no curative therapy currently exists. Pediatric Crohn's disease is characterized by frequent relapses, a wide...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Pediatric Society
2010-09-01
|
| Series: | Korean Journal of Pediatrics |
| Subjects: | |
| Online Access: | http://kjp.or.kr/upload/pdf/kjped-53-830.pdf |
| _version_ | 1811253804083970048 |
|---|---|
| author | Mi Jin Kim Yon Ho Choe |
| author_facet | Mi Jin Kim Yon Ho Choe |
| author_sort | Mi Jin Kim |
| collection | DOAJ |
| description | Crohn's disease is characterized by chronic inflammation involving any portion of the gastrointestinal tract. Treating Crohn's disease is a major challenge for clinicians, as no curative therapy currently exists. Pediatric Crohn's disease is characterized by frequent relapses, a wide extent of disease, a high prevalence of extraintestinal manifestations, and a severe clinical course. The classic therapeutic approach is known as the 'step-up' strategy, and follows a progressive course of treatment intensification as disease severity increases. Although this approach is usually effective for symptom control, many patients become either resistant to or dependent on corticosteroids. The efficacy of infliximab suggests that, rather than a progressive course of treatment, early intense induction may reduce complications associated with conventional treatment and improve quality of life. Intensive early therapy with infliximab is known as the 'top-down' strategy. Such therapy offers the potential for altering the natural history of Crohn's disease, and is changing treatment paradigms. However, the relatively new concept of an early aggressive or 'top-down' treatment approach is not yet widely accepted, especially in pediatric patients. The results of our current study demonstrate that early and intensive treatment of pediatric Crohn's disease patients with infliximab, at initial diagnosis, was more effective for maintaining remission and reducing flares. |
| first_indexed | 2024-04-12T16:56:51Z |
| format | Article |
| id | doaj.art-86f48cf6e6af411ea986706790aa6eb5 |
| institution | Directory Open Access Journal |
| issn | 1738-1061 2092-7258 |
| language | English |
| last_indexed | 2024-04-12T16:56:51Z |
| publishDate | 2010-09-01 |
| publisher | Korean Pediatric Society |
| record_format | Article |
| series | Korean Journal of Pediatrics |
| spelling | doaj.art-86f48cf6e6af411ea986706790aa6eb52022-12-22T03:24:12ZengKorean Pediatric SocietyKorean Journal of Pediatrics1738-10612092-72582010-09-0153983083310.3345/kjp.2010.53.9.8302010530903Change in the treatment strategy for pediatric Crohn's diseaseMi Jin Kim0Yon Ho Choe1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.Crohn's disease is characterized by chronic inflammation involving any portion of the gastrointestinal tract. Treating Crohn's disease is a major challenge for clinicians, as no curative therapy currently exists. Pediatric Crohn's disease is characterized by frequent relapses, a wide extent of disease, a high prevalence of extraintestinal manifestations, and a severe clinical course. The classic therapeutic approach is known as the 'step-up' strategy, and follows a progressive course of treatment intensification as disease severity increases. Although this approach is usually effective for symptom control, many patients become either resistant to or dependent on corticosteroids. The efficacy of infliximab suggests that, rather than a progressive course of treatment, early intense induction may reduce complications associated with conventional treatment and improve quality of life. Intensive early therapy with infliximab is known as the 'top-down' strategy. Such therapy offers the potential for altering the natural history of Crohn's disease, and is changing treatment paradigms. However, the relatively new concept of an early aggressive or 'top-down' treatment approach is not yet widely accepted, especially in pediatric patients. The results of our current study demonstrate that early and intensive treatment of pediatric Crohn's disease patients with infliximab, at initial diagnosis, was more effective for maintaining remission and reducing flares.http://kjp.or.kr/upload/pdf/kjped-53-830.pdfCrohn's diseaseChildTreatment |
| spellingShingle | Mi Jin Kim Yon Ho Choe Change in the treatment strategy for pediatric Crohn's disease Korean Journal of Pediatrics Crohn's disease Child Treatment |
| title | Change in the treatment strategy for pediatric Crohn's disease |
| title_full | Change in the treatment strategy for pediatric Crohn's disease |
| title_fullStr | Change in the treatment strategy for pediatric Crohn's disease |
| title_full_unstemmed | Change in the treatment strategy for pediatric Crohn's disease |
| title_short | Change in the treatment strategy for pediatric Crohn's disease |
| title_sort | change in the treatment strategy for pediatric crohn s disease |
| topic | Crohn's disease Child Treatment |
| url | http://kjp.or.kr/upload/pdf/kjped-53-830.pdf |
| work_keys_str_mv | AT mijinkim changeinthetreatmentstrategyforpediatriccrohnsdisease AT yonhochoe changeinthetreatmentstrategyforpediatriccrohnsdisease |